Literature DB >> 15732534

Technology evaluation: SB-485232, GlaxoSmithKline.

Jakub Golab1, Tomasz Stoklosa.   

Abstract

GlaxoSmithKline (formerly SmithKline Beecham), under license from Hayashibara, is developing SB-485232, a recombinant human interleukin-18 cancer immunotherapy for the potential treatment of immunologically sensitive cancers, including melanoma and renal cell cancer. The compound is currently undergoing phase II clinical trials.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15732534

Source DB:  PubMed          Journal:  Curr Opin Mol Ther        ISSN： 1464-8431


  2 in total

Review 1.  Immunomodulatory cytokines as therapeutic agents for melanoma.

Authors:  Courtney Nicholas; Gregory B Lesinski
Journal:  Immunotherapy       Date:  2011-05       Impact factor: 4.196

2.  Novel Reporter System Monitoring IL-18 Specific Signaling Can Be Applied to High-Throughput Screening.

Authors:  Riho Kurata; Kenji Shimizu; Xiaofeng Cui; Masamitsu Harada; Takayuki Isagawa; Hiroaki Semba; Jun Ishihara; Koji Yamada; Jun Nagai; Yasuhiro Yoshida; Norihiko Takeda; Koji Maemura; Tomo Yonezawa
Journal:  Mar Drugs       Date:  2020-01-17       Impact factor: 5.118
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.